Q-omics provides the consensus-scored CASC3 profile across patient tissues and cancer cell-line models. CASC3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CASC3 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, CASC3 protein abundance shows 25,584 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, LIHC, and LSCC as cancer lineages where CASC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASC3 survival associations across molecular data types. CASC3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASC3 RNA expression–survival associations across cancer types. High CASC3 expression shows unfavorable associations in ACC, LIHC and KICH, but favorable associations in UCS, READ and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for CASC3 RNA expression.
This table summarizes CASC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CASC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASC3 shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, HNSC, COAD and CHOL. The LIHC box plot shows higher CASC3 RNA expression in tumor versus normal tissue (log2 FC = +1.447, t-test p < 0.001).
This table shows molecular features associated with CASC3 in patient tissues and cancer cell lines. In patient samples, CASC3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CASC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
